June 29, 2018 09:19 AM EDTUpdated 09:30 AM

Acne was a bust, but excessive sweating scores FDA OK for Dermira — shares climb

Brittany Meiling

After a catastrophic failure in acne that obliterated its stock just months ago, Dermira $DERM had some redeeming news this morning — the FDA has OK …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Acne was a bust, but excessive sweating scores FDA OK for Dermira — shares climb

Brittany Meiling

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Caltech spinout debuts with AI-driven 'mirror peptide' platform

Are programs with compounded GLP-1s safe for your population?

Ac­ne was a bust, but ex­ces­sive sweat­ing scores FDA OK for Der­mi­ra — shares climb

Brittany Meiling

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Acne was a bust, but excessive sweating scores FDA OK for Dermira — shares climb

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Caltech spinout debuts with AI-driven 'mirror peptide' platform

Are programs with compounded GLP-1s safe for your population?